MNNGF (Baijin Life Science Holdings) Current Deferred Revenue: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNNGF Baijin Life Science Holdings Ltd MNNGF
33 GF Score
Price $0.08
GF Value $0.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Baijin Life Science Holdings Current Deferred Revenue?

Baijin Life Science Holdings MNNGF 33 Current Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus rates MNNGF with a GF Score™ of 33/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Baijin Life Science Holdings's current deferred revenue for the quarter that ended in Mar. 2026 was $0.00 Mil.

Baijin Life Science Holdings Current Deferred Revenue Related Terms

Baijin Life Science Holdings Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Baijin Life Science Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baijin Life Science Holdings Current Deferred Revenue Chart

Baijin Life Science Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Baijin Life Science Holdings Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MNNGF
33GF Score
Baijin Life Science Holdings Ltd MNNGF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Baijin Life Science Holdings (MNNGF) has a Current Deferred Revenue of $0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Baijin Life Science Holdings and its competitors.
Is Baijin Life Science Holdings' Current Deferred Revenue too high?
Baijin Life Science Holdings' current Current Deferred Revenue is $0.00 Mil. Overall, Baijin Life Science Holdings has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' Current Deferred Revenue compare to TPR?
Baijin Life Science Holdings' Current Deferred Revenue of $0.00 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Retail - Cyclical company?
A good Current Deferred Revenue depends on the Retail - Cyclical industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Baijin Life Science Holdings and its competitors. Baijin Life Science Holdings's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, Baijin Life Science Holdings (MNNGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.08 — trading 60% above its estimated fair value. The current Current Deferred Revenue is $0.00 Mil. Baijin Life Science Holdings' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current Current Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?

Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued. The current stock price of $0.08 is trading 60% above its estimated GF Value™ of $0.05. GuruFocus considers Baijin Life Science Holdings to be Significantly Overvalued.

Key valuation signals for MNNGF:

  • Current Deferred Revenue: $0.00 Mil
  • GF Value™: $0.05 vs. price of $0.08 (60% above fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Baijin Life Science Holdings Business Description

Other Exchanges 01466:Hong Kong
Address 66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
33GF Score

Get the complete analysis for MNNGF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.05
GF Value